About
Technology
About Halneuron®
Mechanism of Action
About Pain
Publications
Media
Clinical Trials
Clinical Experience
Ongoing Trials
Physician Resources
Expanded Access Policy
Investors
Investment and Partnership Opportunities
Corporate Presentation
News & Media
Magazine & Stories
Contact
中文
Menu
About
Technology
About Halneuron®
Mechanism of Action
About Pain
Publications
Media
Clinical Trials
Clinical Experience
Ongoing Trials
Physician Resources
Expanded Access Policy
Investors
Investment and Partnership Opportunities
Corporate Presentation
News & Media
Magazine & Stories
Contact
中文
Clinical Experience
Clinical Experience
Protocol
MLP-001
Location
China
Clinical Phase
Phase I
Indication
Healthy Volunteers
Completed
Protocol
WEX-US-001
Location
Canada / US
Clinical Phase
Phase I
Indication
PK study in Healthy
Male Volunteers
Completed
Protocol
WEX-001
Location
Canada
Clinical Phase
Phase I
Indication
Healthy Volunteers
Completed
Protocol
WEX-002
Location
Canada
Clinical Phase
Phase I
Indication
Healthy Volunteers
Completed
Protocol
WEX-015
Location
Canada
Clinical Phase
Phase I
Indication
Healthy Volunteers
Completed
Protocol
MLP-002
Location
China
Clinical Phase
Phase IIa
Indication
Cancer Patients (Refractory Pain)
Completed
Protocol
WEX-003
Location
Canada
Clinical Phase
Phase IIa
Indication
Cancer Patients (Refractory Pain)
Completed
Protocol
WEX-008
Location
Canada
Clinical Phase
Phase IIa
Indication
Cancer Patients (Refractory Pain)
Completed
Protocol
WEX-014
Location
Canada
Clinical Phase
Phase IIb
Indication
Cancer Patients (Refractory Pain)
Completed
Protocol
WEX-014OL
Location
Canada
Clinical Phase
Phase IIb
Indication
Cancer Patients (Refractory Pain)
Completed
Protocol
TEC-006
Location
Canada/Australia/
New Zealand
Clinical Phase
Phase III
Indication
Cancer Patients (Refractory Pain)
Completed
Protocol
TEC-006OL
Location
Canada/Australia/New Zealand
Clinical Phase
Phase III
Indication
Cancer Patients (Refractory Pain)
Completed
Protocol
TTX-CINP-201-PK
Location
United States
Clinical Phase
Phase I
Indication
PK Study in Healthy Volunteers
Completed
Protocol
TTX-CINP-201
Location
United States
Clinical Phase
Phase II
Indication
Chemotherapy-Induced Neuropathic Pain
Completed
Protocol
TTX-TQT-101
Location
United States
Clinical Phase
Phase I
Indication
Cardiovascular Effect of Tetrodotoxin in Healthy Volunteers
Completed